don’t be too quick to lower cholesterol levels

1
Don't be too quick to lower cholesterol levels VIEWS & REVIEWS The wisest decision would be to limit antihypercholesterolaemic therapy to those who need it most, according to Dr NM Kaplan from The University of Texas Southwestern Medical Centre, USA on reviewing data from 6 primary intervention trials. Cholesterol lowering has been shown to reduce mortality from coronary heart disease (along with reductions in nonfatal coronary events) but has not been shown to reduce overall mortality; death from cancer and violent deaths including accidents and suicides have reportedly increased with antihypercholesterolaemic therapy. The overall benefits of reducing cholesterol levels are limited. It seems that the majority of people favour the reduction of cholesterol levels by dietary measures alone in the patients whose cholesterol levels are only minimally increased. In addition, the costs of treating all mildly hypercholesterolaemic patients with antihypercholesterolaemics are considerable even though health economists conclude that the costs of reducing cholesterol levels with drugs compares favourably with those of other widely used interventions. Kaplan NM. Lipid intervention trials in primary prevention: a critical review. Clinical and Experimental Hypertension Part A - Theory and Practice A14: 109-118, No. 1-2. 1992 [23 references) "13 ISSN 0156-2703/92/0222-0003/$1.00/0 © Adis Intemationoilld 3 INPHARMA® 22 Feb 1992

Upload: leanh

Post on 16-Mar-2017

215 views

Category:

Documents


1 download

TRANSCRIPT

Page 1: Don’t be too quick to lower cholesterol levels

Don't be too quick to lower cholesterol levels

VIEWS & REVIEWS

The wisest decision would be to limit antihypercholesterolaemic therapy to those who need it most, according to Dr NM Kaplan from The University of Texas Southwestern Medical Centre, USA on reviewing data from 6 primary intervention trials.

Cholesterol lowering has been shown to reduce mortality from coronary heart disease (along with reductions in nonfatal coronary events) but has not been shown to reduce overall mortality; death from cancer and violent deaths including accidents and suicides have reportedly increased with antihypercholesterolaemic therapy.

The overall benefits of reducing cholesterol levels are limited. It seems that the majority of people favour the reduction of cholesterol levels by dietary measures alone in the patients whose cholesterol levels are only minimally increased. In addition, the costs of treating all mildly hypercholesterolaemic patients with antihypercholesterolaemics are considerable even though health economists conclude that the costs of reducing cholesterol levels with drugs compares favourably with those of other widely used interventions. Kaplan NM. Lipid intervention trials in primary prevention: a critical review. Clinical and Experimental Hypertension Part A - Theory and Practice A14: 109-118, No. 1-2. 1992 [23 references) "13

ISSN 0156-2703/92/0222-0003/$1.00/0 © Adis Intemationoilld

3

INPHARMA® 22 Feb 1992